Immunohistochemical Analysis of Nicotinamide Phosphoribosyltransferase Expression in Gastric and Esophageal Adenocarcinoma (AEG)
Open Access
- 13 December 2022
- journal article
- research article
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 4 (4) , 333-340
Abstract
Nicotinamide phosphoribosyltransferase (NAMPT) represents a major component in cellular energy metabolism, which is also crucial for cancer cells that have elevated aerobic glycolysis; moreover, targeting the NAD salvage pathway by inhibition of NAMPT was shown effective in a subgroup of gastric cancer cell lines. In order to study the expression levels of NAMPT in adenocarcinoma of the esophagogastric junction and stomach (AEG/S) we performed immunohistochemical analysis in a cohort of 296 tumor samples using tissue-microarrays (TMAs). In the present investigation, we saw a high expression of NAMPT in only a minority of our large AEG/S cohort. Although we did not find a correlation between NAMPT expression and survival, subgroup analysis showed that NAMPT expression was more frequent in older patients (>65 years, p = 0.049) and was associated with a numerical shorter survival that did not reach statistical significance within this age group. In conclusion, we did not find significance for any prognostic effect of NAMPT in our AEG/S cohort; however, the evaluation of other NAD metabolic enzymes is needed as molecular predictors of response to potential NAMPT inhibition in the treatment of patients with AEG/S.Keywords
Funding Information
- Berliner Krebsgesellschaft (TRFF201501)
This publication has 34 references indexed in Scilit:
- FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cellsBiochemical and Biophysical Research Communications, 2015
- Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population – results from the PolSenior substudyMetabolism, 2014
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Characteristics of gastric cancer in AsiaWorld Journal of Gastroenterology, 2014
- Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in MiceCell Metabolism, 2011
- NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress responseOncogene, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: Relevance of a topographic‐anatomic subclassificationJournal of Surgical Oncology, 2005
- The difference in gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions?Critical Reviews in Oncology/Hematology, 2001
- On the Origin of Cancer CellsScience, 1956